UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 20, 2013

Horizon Pharma, Inc.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (224) 383-3000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

On November 20, 2013, we were notified by counsel for Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc. (collectively, “Par”) that Par had elected to withdraw its Abbreviated New Drug Application (“ANDA”) with the U.S. Food and Drug Administration (“FDA”) for a generic version of RAYOS^® containing 2 mg and 5 mg of prednisone. On October 22, 2013, we, together with Jagotec AG, filed suit in the United States District Court for the District of New Jersey against Par in response to a Paragraph IV Patent Certification from Par advising that Par had filed an ANDA with the FDA for a generic version of RAYOS^® containing 2 mg and 5 mg of prednisone. The lawsuit alleges that Par has infringed U.S. Patent Nos. 6,488,960, 6,677,326, 8,168,218, 8,309,124 and 8,394,407 by filing an ANDA seeking approval from the FDA to market generic versions of RAYOS^® prior to the expiration of the patents. We will work with Par to provide a stipulation of dismissal of the case to the Court. The subject patents are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.